Market Size
The global influenza diagnostics market is estimated at US$ 1,803.30 million in 2025 and is projected to reach US$ 2,874.19 million by 2033, growing at a CAGR of 6.00% during 2026-2033.
Influenza is caused by the flu virus which causes symptoms such as fever, cough, sore throat, etc. It is usually diagnosed by the symptoms caused or by using rapid diagnostic tests that give results within 30 minutes. PCR is the most common procedure for the detection of the virus to date. Several more tests are available in specific laboratories that help determine specific viruses. RIDTs are used for both children and adults and hence, these types of tests are mostly preferred.
Market Scope
| Metrics | Details |
| CAGR | 6.00% |
| Market Size Available for Years | 2022-2031 |
| Estimation Forecast Period | 2024-2031 |
| Revenue Units | Value (US$ Mn) |
| Segments Covered | Disease Type, Test Type, End User |
| Regions Covered | North America, Europe, Asia-Pacific, South America, and Middle East & Africa |
| Largest Region | North America |
| Fastest Growing Region | Asia-Pacific |
| Report Insights Covered | Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and Acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, Porter’s Analysis, Pricing Analysis, Regulatory Analysis, Supply-Chain Analysis and Other key Insights. |
For more details on this report – Request for Sample
Market Dynamics: Drivers & Restraints
Increasing product launches
Product launches are increased to keep up the demand for influenza diagnostic test kits in diagnostic centers and hospitals. The demand rises during the flu season as the flu cases are observed to jump during the flu season. Hence, the launch of test kits
The Becton, Dickinson & Company's BD MAX Respiratory Viral Panel (RVP), a new molecular diagnostic combination test for SARS-CoV-2, Influenza A+B, and Respiratory Syncytial Virus (RSV), was CE-marked.
2San launched a dual kit SARS-CoV-2 & Influenza A+B. The OTC kit is launched to help alleviate the pressure on healthcare institutions.
Lack of Skilled Professionals
The lack of qualified and experienced professionals is expected to hamper the market. Skilled workers and healthcare facilities in middle-income countries are limited which hinders the influenza diagnostics market. Diagnostics procedures should be done accurately with all the measures, or else the test kits may show false positive results due to their specificity which can lead to complications such as wrong treatment or no treatment at all in the diseased individual.
Segment Analysis
The global influenza diagnostics market is segmented based on disease type, test type, end user and region.
RIDT (Rapid Influenza Diagnostic Test) Type is Expected to Dominate Market
RIDT (Rapid Influenza Diagnostic Test) is expected to hold the largest share of the market due to the increasing usage of rapid medical diagnostic test kits due to their reliability and portability. It is easy to use in homecare settings. FDA authorizations and the launch of rapid diagnostic test kits for the detection of viruses increased due to the demand for the RIDTs.
Recent Developments
- April 2025: F. Hoffmann-La Roche Ltd continued expansion of its cobas® respiratory testing portfolio globally, focusing on high-throughput PCR systems capable of detecting influenza strains alongside other respiratory pathogens, supporting centralized laboratories in Europe and Asia.
- March 2025: Abbott Laboratories expanded its rapid respiratory testing portfolio by enhancing multiplex molecular diagnostic platforms capable of simultaneously detecting influenza A, influenza B, and RSV. The update focused on improving turnaround time in point-of-care settings such as urgent care clinics and pharmacies.
- February 2025: QuidelOrtho Corporation strengthened its Sofia® platform offerings by introducing improved antigen-based influenza assays with higher sensitivity thresholds, targeting decentralized testing environments and seasonal surge preparedness across the U.S.
Competitive Landscape
The major global players in the market include Roche Diagnostics Limited, Thermo Fisher Scientific, Inc., Abbott Laboratories, Inc., 3M, Becton, Dickinson, and Company (BD), Hologic, Inc, Danaher Corporation, Biomeurex SA, Siemens Healthineers AG, QIAGEN among others.
Why Purchase the Report?
- To visualize the global influenza diagnostics market segmentation based on disease type, test type, end user and region as well as understand key commercial assets and players.
- Identify commercial opportunities by analyzing trends and co-development.
- Excel data sheet with numerous data points of influenza diagnostics market-level with all segments.
- PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
- Product mapping available as excel consisting of key products of all the major players.
The global influenza diagnostics market report would provide approximately 58 tables, 57 figures and 186 pages.
Target Audience
- Manufacturers/ Buyers
- Industry Investors/Investment Bankers
- Research Professionals
- Emerging Companies
